Cellmid Limited (CDY:ASX)


right-arrow Created with Sketch. -0.002 (-2.15%)
MCAP $11.57M
Last trade 15.47pm 26/02/2021 20mins delayed

Latest Announcements

18/02/2021 Price SensitivePSCDYCellmid Limited
09/02/2021 Price SensitivePSCDYCellmid Limited
25/01/2021 Price SensitivePSCDYCellmid Limited
25/01/2021 Price SensitivePSCDYCellmid Limited
15/01/2021CDYCellmid Limited
04/01/2021CDYCellmid Limited
30/12/2020CDYCellmid Limited
30/12/2020CDYCellmid Limited

Company Overview

Cellmid Limited develops and markets therapies and diagnostic tests for inflammatory and fibrotic diseases, cancer, ischemic diseases of the heart, and hair loss. The Company operates in two segments: research and development of diagnostics and therapeutics, and research, development and marketing of hair growth products. It develops and commercializes diagnostic and therapeutic products for the management of diseases, such as cancer and various chronic inflammatory conditions by targeting midkine (Midkine Businesses, Lyramid and Kinera), and the development and sale of over-the-counter (OTC) treatments to alleviate excessive and abnormal hair loss, and re-establish the natural hair growth cycle (Consumer Health Business). Its products include Midkine ELISA kit; Advangen International hair loss products, and Evolis products, which are a range of hair growth products. The Company, through its subsidiaries, develops and sells treatments for various forms of hair loss (alopecia).

CDY in the news

Search Previous Announcements